title: Metformin and pancreatic cancer: a clue requiring investigation.
abstract: Laboratory models show antineoplastic activity of metformin under certain conditions, and pharmacoepidemiologic studies have reported reduced cancer burden among diabetics taking metformin. Therefore, the hypothesis that metformin has antineoplastic activity is receiving increasing attention. However, gaps in knowledge must be addressed before metformin can be "repurposed" for oncologic indications.
authors.affiliation: Department of Oncology, Lady Davis Institute for Medical Research of the Jewish General Hospital and McGill University, Montreal, Quebec, Canada. michael.pollak@mcgill.ca
authors.forename: Michael
authors.initials: M
authors.lastname: Pollak
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D048909:Diabetes Complications / Q000188:drug therapy; D003920:Diabetes Mellitus / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D008687:Metformin / Q000494:pharmacology / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D007004:Hypoglycemic Agents; D008687:Metformin